<i>ESR1</i> Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention - Concepedia

Concepedia

Publication | Open Access

<i>ESR1</i> Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention

DOI Full Paper Access

12

Citations

46

References

2008

Year

Joseph C. Baker, Julie H. Ostrander, Siya Lem, Gloria Broadwater, Gregory R. Bean, Nicholas C. D’Amato, Vanessa Goldenberg, Craig Rowell, Catherine Ibarra-Drendall, Tracey Grant,

Cancer Epidemiology Biomarkers & Prevention

Abstract

Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

References

	Year	Citations
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham, JNCI Journal of the National Cancer Institute	1998	5.5K
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma James G. Herman, Asad Umar, Kornélia Polyák, Proceedings of the National Academy of Sciences	1998	1.9K
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer C. Kent Osborne, V J Bardou, Torsten Hopp, JNCI Journal of the National Cancer Institute	2003	778
Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 Zeruesenay Desta, Bryan A. Ward, Nadia Soukhova, Journal of Pharmacology and Experimental Therapeutics	2004	641
Biallelic inactivation of <i> hMLH <i>1</i> </i> by epigenetic gene silencing, a novel mechanism causing human MSI cancers Martina Veigl, Lakshmi Kasturi, Joseph Olechnowicz, Proceedings of the National Academy of Sciences	1998	630
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Matthew P. Goetz, Stacey K. Knox, Vera J. Suman, Breast Cancer Research and Treatment Endocrine-related CancerMedicineGynecologyAdjuvant TamoxifenBreast Cancer	2006	550
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Yvonne Ottaviano, Jean‐Pierre J. Issa, Fritz F. Parl, PubMed Systems BiologyAbnormal MethylationBreast OncologyMedicineGenetics	1994	486
Inhibition of protein kinase C by tamoxifen. C A O'Brian, Rob M. J. Liskamp, David H. Solomon, PubMed Molecular PharmacologySignal TransductionProtein Kinase CBiochemistryMedicine	1985	468
Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen Martin Widschwendter, Kimberly D. Siegmund, Hannes Müller, Cancer Research	2004	320
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Charles R. Holst, Gerard J. Nuovo, Manel Esteller, PubMed Epigenetic ChangeGeneticsDna MethylationP16 Promoter HypermethylationEpigenetics	2003	314

Page 1